Reports second quarter revenues of $0.1 billion, GAAP net loss of $(0.8) billion and GAAP EPS of $(2.13) Updates 2025...
Updates
NatHaLi-01 study evaluating eti-cel (UCART20x22) in relapsed or refractory B-cell non-Hodgkin lymphoma (r/r NHL) Partnerships Servier – Anti-CD19 CAR-T In...
There is a very specific panic around summer dressing – all that flesh on show, for starters. So it always...
iTeos Therapeutics Inc. - Topline interim dataset from GALAXIES Lung-201 with >240 patients anticipated in 2Q25 - Interim datasets from...
Phase 2b study completed in amyotrophic lateral sclerosis (ALS) demonstrated lead asset PrimeC slows disease progression and functional decline Ongoing...
CAPE CANAVERAL, Fla., March 31, 2025--(BUSINESS WIRE)--Sidus Space (NASDAQ: SIDU) (the "Company" or "Sidus"), an innovative, agile space mission enabler,...
